RECURSION PHARMACEUTICALS, INC. (RXRX) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Feb 25, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for RECURSION PHARMACEUTICALS, INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, RECURSION PHARMACEUTICALS, INC.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
-22.02%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does RECURSION PHARMACEUTICALS, INC. actually do?
Answer:
Recursion Pharmaceuticals is a clinical-stage TechBio company focused on decoding biology to develop novel medicines. Leveraging its proprietary Recursion Operating System (OS), an AI-native platform, the company integrates multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. This platform aims to accelerate drug discovery and development, reducing the traditional high attrition rates and lengthy timelines. Recursion has advanced a pipeline of wholly-owned and partnered programs targeting oncology and rare diseases, with key clinical readouts and strategic collaborations with major pharmaceutical companies like Sanofi, Roche, and Genentech.
Question:
What are RECURSION PHARMACEUTICALS, INC.'s revenue drivers?
Answer:
Revenue is primarily generated through research and development agreements with strategic partners, including upfront payments, milestone payments upon achievement of specified development and regulatory milestones, and potential royalties on net sales.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required